Method and kit for following neurodegenerative diseases
AssigneeGemac
InventorMichel Geffard
Life of this patent
Estimating the term…
Abstract
The invention relates to a method for detecting and supervising neurodegenerative diseases, which consists in detecting the presence of antibodies of the A-isotype and/or M-isotype which are directed against the antigens which are associated with these diseases. The invention also relates to a kit for the implementation of this method.
Claims15
A method of detecting antibodies which are associated with the occurrence or the progression of a neurodegenerative disease in a biological fluid, which comprises the following steps:
- placing said fluid in contact with each one of the following antigens:
- Pal, Ole, Myr, PI, MAD, Ach, FarCys, Aze, NO-Cys, NO-Tyr, NO-Trp, NO-His, NO2-Tyr, NO-Phe, NO-Arg, NO-Asn, NO-Met, NO-Cr, NO-BSA, Ig3, Ig5, Ig12, Ig13, Ig16, Ig17, Ig19, and
- revelation of the complexes which are optionally formed between said antigens and the corresponding antibodies.
A method of detecting antibodies which are associated with the occurrence or the progression of a neurodegenerative disease in a biological fluid, which comprises the following steps:
- placing said fluid in contact with each one of the following antigens
- PI, Ach, Aze, NO-Cys, NO-Tyr, NO-Trp, NO2-Tyr, NO-Asn, NO-Met, Ig5, Ig12, Ig13, Ig16, Ig17 and Ig19, and
- revelation of the complexes which are optionally formed between said antigens and the corresponding antibodies.
A method of detecting antibodies which are associated with the occurrence or the progression of a neurodegenerative disease in a biological fluid, which comprises the following steps:
- placing said fluid in contact with each one of the following antigens
- Ole, PI, MAD, Aze, NO-Cys, FarCys, Ig3, Ig5, Ig12, Ig13, Ig16 and Ig17, and
- revelation of the complexes which are optionally formed between said antigens and the corresponding antibodies.
A method of detecting antibodies which are associated with the occurrence or the progression of a neurodegenerative disease in a biological fluid, which comprises the following steps:
- placing said fluid in contact with each one of the following antigens:
- Pal, Ole, Myr, PI, MAD, FarCys, Aze, NO-Cys, NO-Phe, Ig3, Ig5, Ig12, Ig13, Ig17 and Ig19, and
- revelation of the complexes which are optionally formed between said antigens and the corresponding antibodies.
Dependencies are inferred from the claim text.